Add this topic to your myFT Digest for news straight to your inbox
It aims to exploit its extraordinary cache of genetic data but changing corporate DNA is hard
WHO member states are struggling to agree the terms of the first global treaty to deal with the threat of another Covid-19
Patients who took Sanofi’s lixisenatide experienced no worsening of motor symptoms
Europe’s regulations have become ‘too burdensome’ and could hinder innovation, argues Michael Lohan
Novo Nordisk and Eli Lilly, plus a clutch of rivals, aim to cut side effects while treating obesity-linked diseases
UK pharma group’s chief has a fresh challenge — persuading investors that its best days are not behind it
Shareholder advisory groups say potential £18.7mn payout is excessive
Not only is the cost-benefit ratio unbeatable, but not to undertake this spending is to court disaster
Aardvark Therapeutics’ drug has been shown in trials to suppress cravings in patients with rare genetic form of obesity
Record shortages of common drugs have countries scrambling for alternatives while patients skip treatments
Danish group seeks to branch out from diabetes and weight loss drugs with Cardior acquisition
Madrigal is the first to win approval for a treatment for a liver disease that affects one in 20
Advocate general of bloc’s top court says decision against world’s biggest gene sequencing group should be annulled
Funding needed to drive innovation and make therapies available to all, says co-discoverer Jennifer Doudna
Lenmeldy gene therapy treats MLD, a condition that attacks the central nervous system of young children
There is an opportunity for local pharma groups, which Nomura says could take a fifth of the market by 2033
Ruth McKernan aims to make country a hub for research into the condition and accelerate development of new drugs
Acquisition gives pharmaceutical group mid-stage asset to challenge Novartis in new form of cancer care
WuXi AppTec’s business in America under threat by proposed national security legislation
Officials warn weaknesses in surveillance will hinder vaccine development as countries struggle to agree accord
Eli Lilly and Novo Nordisk’s weight-loss drugs have transformed their fortunes but a backlash could be looming
Retail group agrees first partnership with a big drug company since launching online pharmacy business in 2020
Booming sector raises tough questions for ESG investors
We risk forgetting the lessons of the Covid pandemic
Breakthrough medicine will now be subject to further review by committee of independent experts
International Edition